Monitor upcoming topline data from the Phase 2a PreciSION CF trial and Phase 1 dual combination trial, expected this summer, these are the primary catalysts for SION. The current cash runway into 2028 provides ample time for data readouts without near-term financing risk.
Drugs in focus
SION drug pipeline →SION-2222
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
- Time to market
- At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
- Next catalyst
- None dated
What to watchThe next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $49.61entry
- T+1 · 3mo ago +2.88%α +2.27% · $51.04
- T+5 · 3mo ago −86.82%α −88.03% · $6.54
- T+20 · 3mo ago −86.39%α −86.99% · $6.75
- T+60 · 18d ago −92.20%α −90.53% · $3.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wider than the $18.1M loss in Q2 2025, driven by increased R&D and G&A spending. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech, with no new clinical data or guidance changes, both key pipeline trials remain on track for topline data this summer. Cash burn continues as expected, with $268.3M in cash funding operations into 2028, making this a neutral event with no material surprise vs expectations.
Key Financial Metrics
Key Facts
- Net loss of $29.9M for Q2 2026 vs $18.1M in Q2 2025, driven by higher R&D ($21.9M vs $15.4M) and G&A ($10.6M vs $6.5M) expenses.
- Cash, cash equivalents, and marketable securities totaled $268.3M as of June 30, 2026, expected to fund operations into 2028.
- PreciSION CF Phase 2a trial of SION-719 and Phase 1 dual combination trial of SION-451 both remain on track for topline data in summer 2026.
- EPS of $-0.66 for Q2 2026 vs consensus estimate of $-0.64 (a 3.1% miss).
- No revenue reported; company is a pre-revenue clinical-stage biopharmaceutical company.
Financial Impact
Net loss widened by $11.8M YoY to $29.9M; cash burn of $42M in H1 2026 vs $24M in H1 2025; no revenue
Risk Factors
- Phase 2a and Phase 1 trial data may fail to meet efficacy or safety endpoints, which would significantly impair the stock.
- Widening net losses and increasing cash burn rate could necessitate future dilutive financing if timelines extend beyond current cash runway.
- Competitive landscape from existing CFTR modulators (e.g., Trikafta) may limit commercial potential even if trials succeed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-053832 |
| Document: sion-20260806.htm | 0001628280-26-053832 |
| Document: 0001628280-26-053832-index-headers.html | 0001628280-26-053832 |
| Document: 0001628280-26-053832-index.html | 0001628280-26-053832 |
| Document: 0001628280-26-053832.txt | 0001628280-26-053832 |
| 8-K Data (Synthetic) | 0001628280-26-053832 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Viewing Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers